| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2015: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2013: ¥5,980,000 (Direct Cost: ¥4,600,000、Indirect Cost: ¥1,380,000)
|
|---|
| Outline of Final Research Achievements |
Mutations in the LNK/SH2B3 gene are found in myeloproliferative disease patients, and LNK/SH2B3 polymorphisms have been reported to be associated with several autoimmune diseases and cardiovascular diseases. The intracellular adaptor Lnk/Sh2b3 regulates cytokine signals that control lymphohematopoiesis, However, the functions of Lnk/Sh2b3 related to autoimmune inflammation or cardiovascular dysfunction have not been understood. We have revealed that the ability of DCs to support Th1 response was altered by Lnk-deficiency. We have shown that Lnk/Sh2b3 plays a role in preventing pathogenic expansion and activation of CD8+ T cells leading to intestinal tissue damage in Lnk-/- mice. IFN-gamma-producing CD8+ T cells were increased in kidney and arteries, resulting in increased susceptibility for hypertension. We also found that Lnk-/- mice showed impaired glucose tolerance that was largely depend on the abnormality of hematopoietic cells.
|
